Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
prolong ejaculation.
Popular Articles

CytRx Drug Candidate INNO-206 Results In Ovarian Tumor Shrinkage In Animal Trials
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, announced that results demonstrating that its cancer drug candidate INNO-206 caused statistically significant tumor shrinkage in an animal model of ovarian cancer have been accepted for publication in the peer-reviewed journal Investigational New Drugs. The manuscript based on this animal trial, "INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model," was made available ahead of journal printing in electronic format in the January 8, 2009 on-line issue of Investigational New Drugs.
generic viagra
First Cancer Congress Update A Huge Success
The 2009 Cancer Congress Update held at the Park Plaza hotel in central London was hailed a resounding success by clinicians from the worlds of breast, colorectal, lung, prostate and haematological cancer.
News of the day
Identifying Pathways In The Brain To Understand The Underlying Molecular Mechanism Of Huntington's Disease
Florida Atlantic University researcher Dr. Jianning Wei, assistant professor of biomedical sciences in the Charles E. Schmidt College of Biomedical Science at FAU, has received a grant from the National Institutes of Health (NIH) to further her research into the molecular mechanisms of Huntington"s disease (HD). Named after American physician George Huntington, HD is a highly complex genetic, neurological disorder that causes certain nerve cells in the brain to waste away. The disease, characterized by a selective loss of neurons in the brain, affects the basal ganglia, which controls motor control, cognition, learning and emotions. It also affects the outer surface of the brain, or the cortex which controls thought, perception, and memory. Wei and her colleagues are working to identify the pathways in the brain that are altered in response to mutant proteins, as well as to understand the cellular processes impacted by the disease in order to facilitate the development of effective pharmacological interventions.
Health Insurance

Amino Acid May Help Treat Patients With Hair-Pulling Condition

The amino acid N-acetylcysteine appears to reduce symptoms of compulsive hair-pulling in patients with a condition known as trichotillomania, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals. Trichotillomania has been described for almost 200 years and researched for more than two decades, but there is currently no approved treatment for the condition, according to background information in the article. "Trichotillomania is characterized by the following diagnostic criteria: the recurrent pulling out of one"s hair, which results in noticeable hair loss; an increasing sense of tension immediately before pulling out the hair or when attempting to resist the behavior; and pleasure, gratification or relief when pulling out hair," the authors write. "Psychosocial problems are common in individuals with trichotillomania and include significantly reduced quality of life, reduced work productivity and impaired social functioning." The amino acid N-acetylcysteine has previously shown promise in the treatment of repetitive or compulsive disorders and acts on the glutamate system, the largest neurotransmitter system in the human brain, the authors note. Jon E. Grant, J.D., M.D., M.P.H., and colleagues at the University of Minnesota School of Medicine, Minneapolis, conducted a 12-week, double-blind controlled trial of the medication among 50 individuals with trichotillomania (45 women and five men, average age 34.3 years). Twenty-five were randomly assigned to receive 1,200 milligrams to 2,400 milligrams of N-acetylcysteine per day for 12 weeks; the other 25 received placebo. After 12 weeks, patients taking the active medication had significantly greater reductions in hair-pulling symptoms than those taking placebo. "Fifty-six percent of patients "much or very much improved" with N-acetylcysteine use compared with 16 percent taking placebo," the authors write. "Significant improvement was initially noted after nine weeks of treatment." None of the participants reported adverse effects. The magnitude of improvement observed in patients taking N-acetylcysteine was higher than that seen with other medications and similar to that reported for cognitive behavior therapy alone or combined with medication, suggesting that N-acetylcysteine compares favorably with existing treatment options, the authors note. Its efficacy lends further support to the hypothesis that therapies manipulating the glutamate system (called glutamatergic agents) may target core symptoms of compulsive behaviors. "N-acetylcysteine is an amino acid, is available in health-food stores, is cheaper than most insurance co-payments and seems to be well-tolerated. N-acetylcysteine could be an effective treatment option for people with trichotillomania," the authors write. Future studies should evaluate long-term effects of the treatment as well as its efficacy when combined with behavioral therapy, they conclude. "As effective treatments for hair pulling emerge, it becomes increasingly important that physicians and mental health care providers screen for trichotillomania to provide timely treatment." Arch Gen Psychiatry. 2009;66[7]:756-763. Archives of General Psychiatry


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009